TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23392919

Group type: EXPERIMENTAL
Intervention: VIDEO group watched video clips showing repetitive finger movements paced at 3 Hz
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ACOUSTIC group listened to an acoustic cue paced at 3 Hz
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham intervention (static hand video)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: On and off medication states (for VIDEO group)
Number of subjects: 20
Study: 22134562

Group type: EXPERIMENTAL
Intervention: CLNP 1.2%-BPO 3% gel
Number of subjects: 1319

Group type: COMPARATOR
Intervention: CLNP 1.2% gel
Number of subjects: 1319

Group type: COMPARATOR
Intervention: BPO 3% gel
Number of subjects: 1319

Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 1319

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 1319
Study: 19549737

Group type: EXPERIMENTAL
Intervention: NaCl supplementation (100 mmol/day) during telmisartan treatment with or without HCT
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo during telmisartan treatment with or without HCT
Number of subjects: 32
Study: 17539709

Group type: EXPERIMENTAL
Intervention: PRP + ABBM + GTR
Number of subjects: 24

Group type: COMPARATOR
Intervention: ABBM + GTR
Number of subjects: 24
Study: 15085888

Group type: EXPERIMENTAL
Intervention: 200 mg/day of docosahexaenoic acid (DHA) supplementation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (non-supplemented)
Number of subjects: 20
Study: 15887725

Group type: EXPERIMENTAL
Intervention: Topical itraconazole (1%)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Topical and systemic itraconazole
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 54
Study: 10767783

Group type: EXPERIMENTAL
Intervention: Counseling and genetic testing for BRCA1 and BRCA2 mutations
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Counseling and genetic testing
Number of subjects: 213
Study: 9088580

Group type: EXPERIMENTAL
Intervention: Cigarette smoking, 16 cigarettes/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine, 15 mg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray, 24-1 mg doses/day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo nicotine nasal spray, 24 doses/day
Number of subjects: 12
Study: 7680306

Group type: EXPERIMENTAL
Intervention: Chemotherapy (COPP/ABVD scheme, with or without mediastinal irradiation)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (25 patients with normal hearts)
Number of subjects: 49
Study: 3749604

Group type: EXPERIMENTAL
Intervention: Aceglutamide aluminum (N‐acetyl‐L‐glutamine aluminum complex) administered in multiple daily doses (total of 3290 mg over 14 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Aceglutamide aluminum
Number of subjects: 12
Study: 29750760

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine transversus abdominis plane block
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Bupivacaine pain pump
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 21
Study: 26862079

Group type: EXPERIMENTAL
Intervention: Alcohol assessment
Number of subjects: 17266

Group type: EXPERIMENTAL
Intervention: Advice to cut back on drinking
Number of subjects: 17266

Group type: EXPERIMENTAL
Intervention: Information about treatment for alcohol abuse
Number of subjects: 17266

Group type: EXPERIMENTAL
Intervention: Information about treatment for alcohol dependence
Number of subjects: 17266
Study: 25413081

Group type: EXPERIMENTAL
Intervention: Androstenedione and testosterone levels in acne cases
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: 17α-hydroxyprogesterone (17-OHP) levels in male acne cases
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Estradiol levels in female acne cases
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Higher levels of androstenedione and testosterone
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Higher levels of 17-OHP
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Higher levels of estradiol
Number of subjects: 430
Study: 23534177

Group type: EXPERIMENTAL
Intervention: Distraction techniques (toy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distraction techniques (music)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 20356492

Group type: EXPERIMENTAL
Intervention: Recombinant human tissue-type plasminogen activator (rt-PA) 50 mg
Number of subjects: 118

Group type: COMPARATOR
Intervention: Recombinant human tissue-type plasminogen activator (rt-PA) 100 mg
Number of subjects: 118

Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 118
Study: 18397843

Group type: EXPERIMENTAL
Intervention: Surgical trials (n = 18)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Medical trials (n = 81)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Surgical trials (n = 6)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Medical trials (n = 93)
Number of subjects: 114
Study: 15997603

Group type: EXPERIMENTAL
Intervention: Attention Process Training (APT) and attention‐shaping sequence
Number of subjects: 31

Group type: COMPARATOR
Intervention: Equivalent hours of treatment in the same intensive behavioral rehabilitation program
Number of subjects: 31
Study: 12764404

Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs (group DT; 100 patients)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Untreated (group DU; 71 patients)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: ACE-I/ARB treatment in DT group
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Screening for microalbuminuria
Number of subjects: 171
Study: 10334417

Group type: EXPERIMENTAL
Intervention: Continuous vectorcardiography ST segment monitoring (cVST) for 24 hours combined with cardiac troponin T (cTnT) determination.
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Cardiac troponin T (cTnT) determination at admission.
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Prestudy medication with calcium antagonists.
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: One ST segment episode or more during monitoring.
Number of subjects: 232
Study: 1758253

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Intramuscular (IM) analgesia
Number of subjects: 26
Study: 30044247

Group type: EXPERIMENTAL
Intervention: Vilazodone 20 mg/day
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Vilazodone 40 mg/day
Number of subjects: 564

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Vilazodone (combined 20 and 40 mg/day)
Number of subjects: 564
Study: 26531062

Group type: EXPERIMENTAL
Intervention: mTPE (Octonova with Plasmaflo filter)
Number of subjects: 21

Group type: COMPARATOR
Intervention: cTPE (Spectra Optia apheresis system)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: mTPE
Number of subjects: 21

Group type: COMPARATOR
Intervention: cTPE
Number of subjects: 21
Study: 25434609

Group type: EXPERIMENTAL
Intervention: Smith Machine squat (SM)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Barbell back squat (BB)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Tendo-destabilizing bar squat (TBB)
Number of subjects: 14
Study: 22608316

Group type: EXPERIMENTAL
Intervention: Cryotop vitrification of half of mature oocytes
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control oocytes
Number of subjects: 44
Study: 19694628

Group type: EXPERIMENTAL
Intervention: venlafaxine-quetiapine (375 mg/day, 600 mg/day)
Number of subjects: 122

Group type: COMPARATOR
Intervention: venlafaxine
Number of subjects: 122

Group type: COMPARATOR
Intervention: imipramine (plasma-levels 200-300 microg/l)
Number of subjects: 122
Study: 17907276

Group type: EXPERIMENTAL
Intervention: Antidementia drug treatment
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Dementia of the Alzheimer type (DAT)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitors (ChEIs)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Expectations of therapeutic impact
Number of subjects: 122
Study: 16902901

Group type: EXPERIMENTAL
Intervention: In-patient pulmonary rehabilitation (AHB)
Number of subjects: 207
Study: 14659514

Group type: EXPERIMENTAL
Intervention: Opioid blockade (8 mg naloxone i.v.)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 10971304

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine (PSE) 180 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 8638865

Group type: EXPERIMENTAL
Intervention: Spirapril
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 13
Study: 1569238

Group type: EXPERIMENTAL
Intervention: Betaxolol 5 mg once daily
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Betaxolol 10 mg once daily
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Betaxolol 20 mg once daily
Number of subjects: 317

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317
Study: 2997314

Group type: EXPERIMENTAL
Intervention: Wheat bran diet (normal daily intake + 78 gm wheat bran per day)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Cellulose diet (normal daily intake + 30 gm cellulose per day)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Baseline diet (normal daily intake)
Number of subjects: 4
Study: 30383588

Group type: EXPERIMENTAL
Intervention: Optimal ART adherence
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Higher motivation to adhere to ART
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Lower anticipated HIV-related stigma
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Motivation to adhere to ART
Number of subjects: 121
Study: 30203747

Group type: EXPERIMENTAL
Intervention: Intravenous nutrition therapy for observation group infants
Number of subjects: 2400

Group type: COMPARATOR
Intervention: Normal neonates (reference group)
Number of subjects: 2400
Study: 26571162

Group type: EXPERIMENTAL
Intervention: RAND
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: OBS‐S
Number of subjects: 295

Group type: COMPARATOR
Intervention: OBS‐NS
Number of subjects: 295
Study: 25249158

Group type: EXPERIMENTAL
Intervention: Triclosan (Farco-fill® Protect) as a liquid for inflation of catheter balloons
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 84
Study: 22244635

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 5.25% sodium hypochlorite
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 2.5% sodium hypochlorite
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (group 1, n = 4)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Second control group (7 Eppendorf tubes)
Number of subjects: 91
Study: 19844199

Group type: EXPERIMENTAL
Intervention: Half doses of PEG-ES and 12 tablets of 12 mg senna (HDG)
Number of subjects: 296

Group type: COMPARATOR
Intervention: High-dose senna (SG)
Number of subjects: 296
Study: 17272437

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 16227727

Group type: EXPERIMENTAL
Intervention: Steroids
Number of subjects: 56

Group type: COMPARATOR
Intervention: Other medications for ocular complications or pain relief
Number of subjects: 56
Study: 12164986

Group type: EXPERIMENTAL
Intervention: GTN‐HUT in older patients
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: GTN‐HUT in younger patients
Number of subjects: 324

Group type: COMPARATOR
Intervention: GTN‐HUT in older controls
Number of subjects: 324

Group type: COMPARATOR
Intervention: GTN‐HUT in younger controls
Number of subjects: 324
Study: 10208190

Group type: EXPERIMENTAL
Intervention: HFA albuterol
Number of subjects: 469

Group type: COMPARATOR
Intervention: CFC albuterol
Number of subjects: 469
Study: 7598140

Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: ICE
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: HRT and ICE
Number of subjects: 58

Group type: COMPARATOR
Intervention: Calcium alone
Number of subjects: 58

Group type: COMPARATOR
Intervention: No specific therapy
Number of subjects: 58
Study: 2190464

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (IS-5-MN), 20 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 688734

Group type: EXPERIMENTAL
Intervention: 1 mg N acetate and 50 μg EE2 (Minovlar)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 1.05 mg N (Noriday)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 3 mg N acetate and 50 μg EE2 (Gynovlar)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 1 mg N with 50 μg EE2 (intravenous preparation)
Number of subjects: 6
Study: 30669713

Group type: EXPERIMENTAL
Intervention: Mixed-reality navigation combined with three-dimensional visualization technique
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no MR navigation or 3D visualization)
Number of subjects: 50
Study: 29105558

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1.5-2g/day
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC) 0.1mg/kg/day
Number of subjects: 84

Group type: COMPARATOR
Intervention: Both MMF and TAC
Number of subjects: 84
Study: 25418575

Group type: EXPERIMENTAL
Intervention: Internet-based Cognitive Behaviour Therapy (ICBT)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control condition (received ICBT later)
Number of subjects: 101
Study: 22972694

Group type: EXPERIMENTAL
Intervention: Anastrozole plus goserelin
Number of subjects: 197

Group type: COMPARATOR
Intervention: Tamoxifen plus goserelin
Number of subjects: 197
Study: 21377690

Group type: EXPERIMENTAL
Intervention: Usual pharmacotherapy plus aerobic exercise (N = 22)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual pharmacotherapy (N = 11)
Number of subjects: 150
Study: 19218270

Group type: EXPERIMENTAL
Intervention: Resistance training group (n = 21)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (n = 11)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups (Resistance training and Control)
Number of subjects: 32
Study: 16995333

Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg with ethanol (target plasma concentration 0.8 g/kg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Almotriptan 12.5 mg alone
Number of subjects: 16
Study: 12891200

Group type: EXPERIMENTAL
Intervention: Enoxaparin, 100 IU/kg twice daily (n = 220)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Tinzaparin, 175 IU/kg once daily (n = 218)
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 438

Group type: COMPARATOR
Intervention: Tinzaparin
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Enoxaparin and Tinzaparin
Number of subjects: 438
Study: 10553855

Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask airway (ILM)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Standard laryngeal mask airway (LMA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (laryngoscope‐ and fiberscope‐guided oro/nasotracheal intubation)
Number of subjects: 20
Study: 10999065

Group type: EXPERIMENTAL
Intervention: Thyroid dysfunction (Hypothyroid, Hyperthyroid, probable Thyroiditis)
Number of subjects: 132
Study: 1984900

Group type: EXPERIMENTAL
Intervention: Precordial echocardiography
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography
Number of subjects: 93

Group type: COMPARATOR
Intervention: Both echocardiographic techniques
Number of subjects: 93
Study: 6624694

Group type: EXPERIMENTAL
Intervention: L-carnitine oral treatment (2 g/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 14
Study: 30803131

Group type: EXPERIMENTAL
Intervention: DFM30 (tinted daily SPF‐30 facial moisturizer)
Number of subjects: 33
Study: 29274254

Group type: EXPERIMENTAL
Intervention: French Lyophilized Plasma (FLyP)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Fresh Frozen Plasma (FFP)
Number of subjects: 48
Study: 27112783

Group type: EXPERIMENTAL
Intervention: 4 × 10(6) IU interferon beta‐1b for 24 weeks
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: 8 × 10(6) IU interferon beta‐1b for 24 weeks
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study: 24224882

Group type: EXPERIMENTAL
Intervention: Maternal dietary counseling to increase intake of unsaturated fatty acids
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no dietary counseling)
Number of subjects: 90
Study: 21544087

Group type: EXPERIMENTAL
Intervention: 320 mg anthocyanins twice daily
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 18629569

Group type: EXPERIMENTAL
Intervention: 1000 mg of calcium plus 800 IU of vitamin D
Number of subjects: 242

Group type: COMPARATOR
Intervention: 1000 mg of calcium
Number of subjects: 242
Study: 17244291

Group type: EXPERIMENTAL
Intervention: Cash and Counseling consumers (treatment group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medicaid services as usual (control group)
Number of subjects: 0
Study: 16084855

Group type: EXPERIMENTAL
Intervention: Real 10‐Hz repetitive transcranial magnetic stimulation to the left dorsolateral prefrontal cortex at 110% individual motor threshold
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Both groups (Real and Sham)
Number of subjects: 28
Study: 12105408

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 14

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 14
Study: 10429745

Group type: EXPERIMENTAL
Intervention: Alosetron
Number of subjects: 0
Study: 7589053

Group type: EXPERIMENTAL
Intervention: Cholestyramine (suspended in water, 3 times a day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no cholestyramine)
Number of subjects: 12
Study: 2695287

Group type: EXPERIMENTAL
Intervention: 50 ug ethinyl estradiol (EE) and 1.0 mg norethindrone (NE)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: 35 ug ethinyl estradiol (EE) and 1.0 mg norethindrone (NE)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: 35 ug ethinyl estradiol (EE) and 0.5 mg norethindrone (NE)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 192
Study: 329422

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (150‐200 mg daily)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Indomethacin (75‐100 mg daily)
Number of subjects: 26
Study: 31306284

Group type: EXPERIMENTAL
Intervention: OTX-101 0.09%
Number of subjects: 1048

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 1048
Study: 27869488

Group type: EXPERIMENTAL
Intervention: co-phenylcaine nasal spray
Number of subjects: 84

Group type: COMPARATOR
Intervention: placebo nasal spray
Number of subjects: 84
Study: 25381790

Group type: EXPERIMENTAL
Intervention: Index intervention (11 home visits, 2 antenatal and 9 postnatally)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Index intervention delivered by trained NHS health visitors
Number of subjects: 167

Group type: COMPARATOR
Intervention: Control group (normal care)
Number of subjects: 167
Study: 23348881

Group type: EXPERIMENTAL
Intervention: Probing dry weight (ultrafiltration group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Shorter dialysis treatment times
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4 hours of delivered dialysis per session
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no probing dry weight)
Number of subjects: 0
Study: 21361808

Group type: EXPERIMENTAL
Intervention: Exercise group (strength training with Thera-Band resistive bands, 16 weeks, 3 times per week)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 87
Study: 19213681

Group type: EXPERIMENTAL
Intervention: Endocrine therapy with zoledronic acid (4 mg IV every 6 months for 3 years)
Number of subjects: 1803

Group type: COMPARATOR
Intervention: Endocrine therapy without zoledronic acid
Number of subjects: 1803

Group type: COMPARATOR
Intervention: Tamoxifen (20 mg orally daily)
Number of subjects: 1803

Group type: COMPARATOR
Intervention: Anastrozole (1 mg orally daily)
Number of subjects: 1803

Group type: EXPERIMENTAL
Intervention: Endocrine therapy with zoledronic acid
Number of subjects: 1803
Study: 17223994

Group type: EXPERIMENTAL
Intervention: Testosterone (200 mg mixed esters)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nandrolone (200 mg nandrolone decanoate)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (2 ml arachis oil vehicle)
Number of subjects: 30
Study: 15154152

Group type: EXPERIMENTAL
Intervention: hands-on Reiki
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: distance Reiki
Number of subjects: 46

Group type: COMPARATOR
Intervention: distance Reiki placebo
Number of subjects: 46
Study: 11700802

Group type: EXPERIMENTAL
Intervention: Viscoelastic artificial tears (VAT) with sodium hyaluronate (0.4%, 0.25%) and chondroitin sulfate
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sodium chloride solution
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Viscoelastic artificial tears (VAT)
Number of subjects: 28
Study: 9150583

Group type: EXPERIMENTAL
Intervention: Perceived procedural fairness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fairness heuristic theory
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experiments conducted
Number of subjects: 0
Study: 8201953

Group type: EXPERIMENTAL
Intervention: Intraperitoneal (IP) insulin delivery
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (B)
Number of subjects: 10
Study: 2740091

Group type: EXPERIMENTAL
Intervention: 5% acyclovir in modified aqueous cream (ACV-MAC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Modified aqueous cream vehicle (control)
Number of subjects: 0
Study: 129002

Group type: EXPERIMENTAL
Intervention: Propranolol (80-160 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12